NicOx ophthalmology strategy back on course after Altacor shrug-off
This article was originally published in Scrip
NicOx has licensed one marketed and two development-stage ocular diagnostic tests from Rapid Pathogen Screening. It is building its own commercial organisation in the US and Europe to market AdenoPlus, RPS's rapid point-of-care diagnostic tear sample-based test for adenoviral conjunctivitis, which is authorised for marketing in the US and EU. The company hopes to acquire or in-license additional ophthalmology products, diagnostic and therapeutic, to market through the same infrastructure in future.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.